.webp&w=3840&q=75)
BeOne announces 4 cancer programs for ESMO 2026
- BeOne Medicines announced new data presentations covering four investigational cancer treatments at ESMO 2026, scheduled for October 23–27 in Madrid.
- BeOne shares closed at US$369.06 on October 16, down 1.34%, before the announcement.
- The company will also present seven TEVIMBRA abstracts covering lung and gastrointestinal cancers, including Phase 3 findings involving ZIIHERA.
BeOne Medicines (NASDAQ:ONC) announced presentations covering four investigational cancer therapies and seven TEVIMBRA abstracts at ESMO 2026 in Madrid.
The presentations follow earlier 2026 clinical disclosures, including Phase 1 findings for BGB-B2033 and BGB-43395 at major oncology conferences.
The program includes BGB-B2033 for liver cancer, BG-C477 and BGB-58067 for selected advanced tumors, and BGB-43395 for breast cancer.
BeOne expects the October 23–27 congress to provide additional clinical evidence.
Seven TEVIMBRA abstracts include Phase 3 HERIZON-GEA-01 data evaluating treatment with ZIIHERA and chemotherapy for HER2-positive gastroesophageal cancer.
Earlier in 2026, BeOne reported Phase 3 HERIZON-GEA-01 survival findings, advanced its CDK4 inhibitor development and disclosed additional investigational gastrointestinal cancer data.
Frequently asked questions
More from United States
Merck raises FY profit outlook as Q3 revenue climbs 5% to $18.1B
Eli Lilly Q3 revenue surges 39% to $24.4 billion as guidance rises
Enterprise Products Q3 EBITDA jumps 16% to $2.8 billion
KBR Q3 revenue rises 5% to $2 billion as adjusted EBITDA grows 12%
Enerflex Q3 free cash flow rises to $102 million as net earnings climb
WTW Q3 revenue rises 8% to $2.46 billion as AI savings plan advances
